Oliver-Thomas Carter, BSc

Adelphi Real World, United Kingdom

Disclosure(s): Adelphi Real World: Employee; ViiV Healthcare: The Adelphi Real World Disease Specific Programme is wholly owned by Adelphi Real World; ViiV healthcare is one subscriber and paid for the analysis

Poster(s):

• (P-474) Effects of Antiretroviral Resistance on Outcomes and Healthcare Resource Use of People with HIV in the United States and Europe – A Real-World Survey
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-538) People with HIV in the US switching to cabotegravir + rilpivirine long-acting (CAB+RPV LA) from oral antiretroviral therapy (ART) have numerous real-world benefits, including high adherence and treatment satisfaction
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT